| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Sue Lightman | |
| Oren Tomkins-Netzer | |||
| Ahmed Al-Janabi | |||
| Rose Gilbert | |||
| P2860 | cites work | Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia | Q28176000 |
| Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study | Q28186001 | ||
| Statin therapy and autoimmune disease: from protein prenylation to immunomodulation | Q28236647 | ||
| Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial | Q29012779 | ||
| Statin-associated ocular disorders: the FDA and ADRAC data | Q30943920 | ||
| Treg lymphocytes in autoimmune uveitis. | Q34273253 | ||
| Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial | Q34327988 | ||
| A tale of two diseases: atherosclerosis and rheumatoid arthritis. | Q54448410 | ||
| Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro | Q71703868 | ||
| Statins as a newly recognized type of immunomodulator | Q73252634 | ||
| RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin | Q79318156 | ||
| Long-term clinical outcome and causes of vision loss in patients with uveitis | Q85230964 | ||
| Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis | Q34523636 | ||
| Statin safety: a systematic review | Q34566154 | ||
| Statin use and reduced cancer-related mortality | Q34645107 | ||
| An assessment by the Statin Intolerance Panel: 2014 update | Q34661723 | ||
| Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? | Q34757699 | ||
| Association between statin use and uveitis: results from the Pacific Ocular Inflammation study | Q35181364 | ||
| Degree, duration, and causes of visual loss in uveitis. | Q35592376 | ||
| Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial | Q35622529 | ||
| The prevalence of sight-threatening uveitis in Scotland | Q35762875 | ||
| Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? | Q35789870 | ||
| Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease | Q35810049 | ||
| The relation between serum lipids and lutein and zeaxanthin in the serum and retina: results from cross-sectional, case-control and case study designs | Q35847931 | ||
| The Association of Statin Use with Age-Related Macular Degeneration Progression: The Age-Related Eye Disease Study 2 Report Number 9 | Q36315753 | ||
| Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial | Q36357176 | ||
| The Association of Statin Use with Cataract Progression and Cataract Surgery: The AREDS2 Report Number 8 | Q36730429 | ||
| Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. | Q36973367 | ||
| Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports | Q37238682 | ||
| Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction | Q37276408 | ||
| The possible impact of uveitis in blindness: a literature survey | Q37323541 | ||
| Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis | Q37914338 | ||
| Statins as modulators of regulatory T-cell biology. | Q38162189 | ||
| Biologic Therapies: Anti-Tumor Necrosis Factor-α, Anti-Interleukins, Rituximab and Others | Q38616356 | ||
| Pleiotropic effects of statins: new therapeutic targets in drug design | Q38825843 | ||
| Statin use and the risk of developing diabetes: a network meta-analysis | Q38859404 | ||
| Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex | Q40484024 | ||
| The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease | Q40684804 | ||
| Understanding autoimmune uveitis through animal models. The Friedenwald Lecture | Q42738957 | ||
| Statin Modulation of Human T-Cell Proliferation, IL-1β and IL-17 Production, and IFN-γ T Cell Expression: Synergy with Conventional Immunosuppressive Agents. | Q42958893 | ||
| Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal transduction | Q43090511 | ||
| Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site | Q43625666 | ||
| Improvement after verteporfin therapy | Q44345061 | ||
| Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score | Q44497544 | ||
| Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease | Q45151895 | ||
| Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier | Q45280900 | ||
| Chronic inflammatory autoimmune disorders and atherosclerosis | Q46259292 | ||
| Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. | Q46310360 | ||
| Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis | Q46919823 | ||
| Pegylated interferon-α-2b reduces corticosteroid requirement in patients with Behçet's disease with upregulation of circulating regulatory T cells and reduction of Th17. | Q48064172 | ||
| Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. | Q51167002 | ||
| P433 | issue | 2 | |
| P921 | main subject | uveitis | Q280027 |
| P304 | page(s) | 33-39 | |
| P577 | publication date | 2017-03-01 | |
| P1476 | title | Statins as anti-inflammatory agents: A potential therapeutic role in sight-threatening non-infectious uveitis | |
| P478 | volume | 2 |
| Q95856528 | Unveiling the Role of Inflammation and Oxidative Stress on Age-Related Cardiovascular Diseases | cites work | P2860 |
Search more.